Biosimilars Council Files Amicus Brief in support of Apotex’s Petition for Certiorari in Amgen v. Apotex


As we covered in a previous post, Apotex has filed a cert. petition asking the Supreme Court to review  the Federal Circuit’s ruling on the BPCIA’s notice provision in Amgen v. Apotex.  Last week, the Biosimilars Council filed an amicus brief in support of Apotex’s petition.  The brief is available here.

In its amicus brief, the Biosimilars Council takes the position that “the Court should grant the petition in Sandoz and hold that biosimilar applicants are never required to wait until license approval to provide a notice of commercial marketing with the failure to do so privately enforceable by a mandatory 180-day injunction,” and that if the Court does grant review in Sandoz, “it should consider granting the petition in this case as well, so that the Court can consider the various factual scenarios in which the notice issue arises.”  The Biosimilars Council adds that “even if this Court decides to deny review in Sandoz, it should take up the first question presented in this case” – i.e., “Whether the Federal Circuit erred in holding that biosimilar applicants that make all disclosures necessary under the BPCIA for the resolution of patent disputes … must also provide the reference product sponsor with a notice of commercial marketing under 42 U.S.C. § 262(l)(8)(A)” – so as “to provide much-needed certainty to current and potential biosimilar manufacturers.”

Stay tuned to the Big Molecule Watch for further updates.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Popular Topics
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.